Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
A Turpin, C Neuzillet, E Colle… - … in medical oncology, 2022 - journals.sagepub.com
Mortality from pancreatic ductal adenocarcinoma (PDAC) is increasing worldwide and
effective new treatments are urgently needed. The current treatment of metastatic PDAC in fit …
effective new treatments are urgently needed. The current treatment of metastatic PDAC in fit …
Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer
PURPOSE The phase III POLO study demonstrated significant progression-free survival
(PFS) benefit for active olaparib maintenance therapy versus placebo for patients with …
(PFS) benefit for active olaparib maintenance therapy versus placebo for patients with …
Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake
T Golan, R Casolino, AV Biankin… - Therapeutic …, 2023 - journals.sagepub.com
Prognosis is generally poor for patients with pancreatic ductal adenocarcinoma. However,
patients with germline BRCA1 or BRCA2 mutations (gBRCAm) may benefit from first-line …
patients with germline BRCA1 or BRCA2 mutations (gBRCAm) may benefit from first-line …
Pancreatic cancer with mutation in BRCA1/2, MLH1, and APC genes: phenotype correlation and detection of a novel germline BRCA2 mutation
MT Vietri, G D'Elia, G Caliendo, L Albanese… - Genes, 2022 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer death
worldwide; most of cases are sporadic, however about 5% to 10% report a hereditary …
worldwide; most of cases are sporadic, however about 5% to 10% report a hereditary …
Long-term survivors after upfront resection for pancreatic ductal adenocarcinoma: an actual 5-year analysis of disease-specific and post-recurrence survival
G Belfiori, S Crippa, A Francesca, M Pagnanelli… - Annals of surgical …, 2021 - Springer
Background Data on long-term actual survival in patients with surgically resected pancreatic
ductal adenocarcinoma (PDAC) are limited. The aim of this study was to evaluate the actual …
ductal adenocarcinoma (PDAC) are limited. The aim of this study was to evaluate the actual …
Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles
Identifying germline BRCA1/2 mutation carriers is vital for reducing their risk of breast and
ovarian cancer. To derive a serum miRNA-based diagnostic test we used samples from 653 …
ovarian cancer. To derive a serum miRNA-based diagnostic test we used samples from 653 …
Outcomes of a 3-year prospective surveillance in individuals at high risk of pancreatic cancer
S Paiella, G Capurso, S Carrara… - Official journal of the …, 2024 - journals.lww.com
METHODS: HRI (subjects with a family history or mutation carriers with/without a family
history were enrolled in 18 centers). They underwent annual magnetic resonance with …
history were enrolled in 18 centers). They underwent annual magnetic resonance with …
Clinical significance of germline pathogenic variants among 51 cancer predisposition genes in an unselected cohort of Italian pancreatic cancer patients
A Puccini, M Ponzano, B Dalmasso, I Vanni, A Gandini… - Cancers, 2022 - mdpi.com
Simple Summary Multigene germline panel testing data, extended beyond BRCA, in
unselected pancreatic cancer patients, are missing in the Italian population. We aimed here …
unselected pancreatic cancer patients, are missing in the Italian population. We aimed here …
[HTML][HTML] Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a …
Background Germline BRCA1-2 pathogenic variants (gBRCA1-2pv)-related pancreatic
ductal adenocarcinoma (PDAC) showed increased sensitivity to DNA cross-linking agents …
ductal adenocarcinoma (PDAC) showed increased sensitivity to DNA cross-linking agents …
The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance in high …
L Archibugi, F Casciani, S Carrara, E Secchettin… - Familial Cancer, 2024 - Springer
Screening programs for early detection and treatment of pancreatic cancer (PC) and its
precursor lesions are increasingly implemented worldwide to reduce disease-specific …
precursor lesions are increasingly implemented worldwide to reduce disease-specific …